Cardiogenesis Corporation (Pink Sheets: CGCP), a market leader in laser transmyocardial revascularization (TMR), announced that it sponsored an educational symposium yesterday in conjunction with the 21st Annual Transcatheter Cardiovascular Therapeutics (TCT) meeting in San Francisco.
The symposium, titled “Opportunities in Refractory Angina” was attended by over 80 cardiologists. The Program Chairman was Christopher J. White MD, Chairman, Department of Cardiovascular Disease Ochsner Clinic, and the faculty included Timothy D. Henry MD Director of Research Minneapolis Heart Institute, Marvin J. Slepian MD, Clinical Professor of Medicine University of Arizona and Michael J. Bates, Cardiothoracic Surgeon Ochsner Clinic.
“The challenge of effectively treating patients with refractory angina is that these patients may be followed by any one of thousands of cardiologists, internists, general practitioners, and at times heart failure specialists. The TCT program was designed to update the cardiology community on clinical options and in the case of Dr. Henry’s presentation, effective strategies for cardiologists to build a refractory angina practice” stated Paul J. McCormick Executive Chairman Cardiogenesis. He continued “we believe we have a solid opportunity for our current technology by working with the cardiology community to develop patient referrals. Considering the early clinical results achieved, we believe that opportunity can significantly increase with the addition of various biologics. We have a meeting scheduled with the FDA on October 21 in Rockville, MD to discuss our IDE submission for our PHOENIX(R) Combination Delivery System.”
About Cardiogenesis Corporation
Cardiogenesis is a medical device company specializing in the therapies for the treatment of chronic cardiac ischemia. The company’s market leading FDA approved Holmium:YAG laser system and disposable fiber-optic accessories are used to perform a surgical procedure known as Transmyocardial Revascularization (TMR) to treat patients suffering from angina. Surgical products and accessories for the Cardiogenesis TMR procedure, which are marketed in the U.S. and around the world, have been shown to reduce angina and improve the quality of life in patients with coronary artery disease.
With the exception of historical information, the statements set forth above include forward-looking statements. Any forward-looking statements in this news release related to the possible effectiveness of the company’s PHOENIX delivery system or other technologies and the planned clinical trials, are based on current expectations and beliefs and are subject to numerous risks and uncertainties, which are discussed in the “Risk Factors” section of the company’s Annual Report on Form 10-K for the year ended December 31, 2008 and the company’s other recent SEC filings. The company disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
Source: Cardiogenesis Corporation